Top Markets
Coin of the day
AVAX Technologies, Inc. AVAX Technologies, Inc.

AVAX Technologies, Inc.

AVXT
Rank in Stocks #41955
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on... AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.
Share Price
$0.00001
Last synced: 2025-12-30
Market Cap
$6.89K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade AVAX Technologies, Inc. (AVXT)

Category

P/S ratio for AVAX Technologies, Inc. (AVXT)
P/S ratio as of 2026 TTM: 0
According to AVAX Technologies, Inc. latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for AVAX Technologies, Inc. from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE